Almirall will co-market the product together with Recordati Espana, the Spanish subsidiary of the Recordati group. The marketing approval authorization request for silodosin was submitted to the European Medicines Agency using the centralized approval procedure during November 2008 and approval is expected in the first half of 2010.
Silodosin was originally developed by Kissei in Japan and has been obtained under license by Recordati for the whole of Europe and for a number of countries in the Middle East and Africa. Recordati also has the right to appoint co-marketers where deemed appropriate.
Giovanni Recordati, chairman and CEO of Recordati, said: “We are delighted to have Almirall as our co-marketer in Spain for this new drug. I am confident that the contribution of Almirall, the Spanish pharmaceutical company, will be fundamental to the success of this new therapeutic option in Spain.”